Solara Active Q1 FY27 Earnings Call — Analysis (NSE: SOLARA)
Q1 FY27 revenue up 20% YoY to ₹384 Cr, highest EBITDA and PAT in 18 quarters; base business sustains strong momentum; Ibuprofen strategic review on track
The take
Q1FY27 Consolidated Revenue ₹384 Cr ( +20% YoY ) . New guidance — FY27 base business revenue growth at least 10% . New story: Base business new revenue plateau .
Results
Consolidated revenue ₹384 Cr (+20% YoY), EBITDA ₹63.5 Cr (+10% YoY), PAT ₹16.3 Cr (+55% YoY); base business revenue ₹307 Cr (+24% YoY) with robust margin profile
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹384 Cr | +20% | yoy · Q1FY27 |
| EBITDA | ₹63.5 Cr | +10% | yoy · Q1FY27 |
| EBITDA Margin | 17% | +80 bps | qoq · Q1FY27 |
| PAT | ₹16.3 Cr | +55% | yoy · Q1FY27 |
| Base Business Revenue | ₹307 Cr | +24% | yoy · Q1FY27 |
| Base Business Gross Margin | 51.3% | +na | point_in_time · Q1FY27 · adjusted ~54.5% excluding pass-through |
| Base Business EBITDA | ₹72 Cr | +8% | yoy · Q1FY27 |
| Ibuprofen EBITDA Margin | -12% | +na | point_in_time · Q1FY27 · marginal sequential improvement |
| Net Debt | ₹479 Cr | −₹135 Cr (22%) | sequential · as of Jun-26 · vs Mar-26 |
| Net Debt-to-EBITDA | 1.9x | +na | point_in_time · Q1FY27 · annualized Q1 EBITDA |
Guidance
Ibuprofen resolution expected by H1 FY27; base business EBITDA margin sustained at ~25%; net debt to decline to ~₹440 Cr by Mar-27
What management committed to
- [Solara] is on track to resolve the [Ibuprofen] business strategic review by H1 FY27 (by end of September quarter). — Q2FY27
- Net debt expected to reduce to sub ₹450 crores, around ₹440 crores by end of March 2027. — sub ₹450 crores, around ₹440-odd crores, Q4FY27
- Solara aspires to be net debt free by FY29. — net debt zero, FY29
- Base business EBITDA margin expected to be 25% plus/minus 1% going forward [for FY27]. — 25% +/- 1%, FY27
- Base business revenue is expected to grow at least 10% year-on-year. — at least 10%, FY27
- Ibuprofen business is expected to have an EBITDA loss in the range of ₹10 crores to ₹15 crores per quarter going forward. — ₹10-15 crores loss, each quarter going forward
- Total capex for FY27 is planned at ₹55-60 crores, of which ₹40 crores is for incremental debottlenecking capex. — ₹55-60 crores, FY27
- Greenfield expansion is not part of the current plan. — current plan (near term)
- [Solara] is putting in measures on S&OP planning to improve inventory norms and working capital efficiency. — going forward
Key themes
Turnaround execution amidst West Asia headwinds and Ibuprofen strategic review
How the narrative shifted
- Base business new revenue plateau: Base business revenues have crossed ₹300 Cr for two consecutive quarters, establishing a sustainable higher base driven by geographic expansion and debottlenecking.
- West Asia input cost and supply disruption: Geopolitical tensions have raised raw material costs and disrupted solvent availability, pressuring margins; management managing via transparent cost pass-through to customers.
- Ibuprofen strategic review unlock: Resolution of the loss-making Ibuprofen business by H1 FY27 is positioned as a key value-unlocking catalyst, removing a persistent drag.
- Balance sheet deleveraging: Rapid net debt reduction (22% in Q1) with a clear line of sight to sub-₹450 Cr by FY27-end and eventual net-debt-free status by FY29.
- Disciplined capex only for debottlenecking: Management explicitly avoids greenfield, directing capital only to debottlenecking high-margin product lines with a payback of 2-3 quarters to maximise ROCE.
- CRAMS and Vizag restructuring on hold: Vizag facility remains mothballed and CRAMS demerger decision deferred to Q2 alongside ibuprofen review, indicating a wait-and-watch approach.
Operational commentary
- Base business revenues crossed ₹300 Cr for two consecutive quarters (Q4FY26 and Q1FY27), establishing a new revenue plateau
- Ibuprofen strategic review on track, definitive resolution expected by H1 FY27 end
- Net debt slashed by ₹135 Cr (22%) in the quarter, aided by ₹100 Cr rights issue final call and ₹35 Cr operational cash flow
- Debottlenecking capex of ~₹40 Cr in FY27 focused on high-margin products with a targeted payback of 2–3 quarters
- Raw material cost and availability pressures from the West Asia crisis being managed via transparent pass-through to customers, with partial acceptance
- Capacity utilisation across three base sites (Cuddalore, Bangalore, Ambernath) at ~70%; Vizag facility remains mothballed
- Growth driven by geographic expansion into new regions and incremental business wins, alongside debottlenecking volumes
- S&OP initiatives being introduced to improve inventory norms and working capital efficiency
Analyst Q&A
Q. Top operational priorities for the next phase of turnaround (12–18 months)
Three levers: expanding existing business/seeding new business, driving operational efficiency through debottlenecking, and optimising working capital to generate free cash.
Q. Is the September quarter (H1) timeline for Ibuprofen strategic review still on track?
We are working towards an optimum solution and feel fairly confident; we would like to address this question in the September time.
Q. Will the base business EBITDA margin trajectory of 25% sustain in FY27?
25% plus/minus 1% should be the margin profile we’re looking at in terms of EBITDA profile.
Q. Can you elaborate on the impact of US tariff announcements and fuel cost volatility?
No formal policy yet, only intent; awaiting clarity on product scope. Fuel/input cost pass-through managed transparently with customers.
Q. How much capital is deployed in Ibuprofen, and can we expect to recover it?
Deployed capital ~₹700 Cr. Expecting entire capital back is farfetched; the exact cut will be clear with Q2 results.
Q. Is the revenue increase essentially flat quarter-on-quarter?
API industry has Q1 seasonality; adjusted for pass-through costs, YoY growth is 18–19% which is healthier and sustainable.
Q. Any update on the enzymatic route for Ibuprofen?
We do not have Ibuprofen manufactured via enzymatic route.
Research and educational content only. Not investment advice.